Statement of Changes in Beneficial Ownership (4)
January 25 2022 - 02:01PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Rojas-Caro Sandra |
2. Issuer Name and Ticker or Trading Symbol
NeuBase Therapeutics, Inc.
[
NBSE
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Medical Officer |
(Last)
(First)
(Middle)
C/O 350 TECHNOLOGY DRIVE, FOURTH FLOOR |
3. Date of Earliest Transaction
(MM/DD/YYYY)
1/24/2022 |
(Street)
PITTSBURGH, PA 15219
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Employee stock option (right to buy) | $1.58 | 1/24/2022 | | A | | 44592 | | (1) | 1/24/2032 | Common stock | 44592 | $0 | 44592 | D | |
Explanation of Responses: |
(1) | 1/4th of the total shares shall vest on the first anniversary of January 24, 2022, and the remaining shares shall vest on an equal monthly basis over the following 36 months; provided that vesting shall only occur on a scheduled vesting date if employment has not terminated prior to such vesting date. |
Remarks: The power of attorney under which this form was signed is on file with the U.S. Securities and Exchange Commission. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Rojas-Caro Sandra C/O 350 TECHNOLOGY DRIVE, FOURTH FLOOR PITTSBURGH, PA 15219 |
|
| Chief Medical Officer |
|
Signatures
|
/s/ Dietrich Stephan, as attorney-in-fact for Sandra Rojas-Caro | | 1/25/2022 |
**Signature of Reporting Person | Date |
NeuBase Therapeutics (NASDAQ:NBSE)
Historical Stock Chart
From Feb 2024 to Mar 2024
NeuBase Therapeutics (NASDAQ:NBSE)
Historical Stock Chart
From Mar 2023 to Mar 2024